HIV-Infekt pp 95-100 | Cite as

Immunrekonstitution bei stark immunsupprimierten Patienten unter HAART — die kritischen ersten Monate

  • C. Hoffmann
  • O. Degen
  • H. A. Horst
  • J. van Lunzen
  • H.-J. Stellbrink
Conference paper

Zusammenfassung

Seit der Einführung von HAART sind die Inzidenzen opportunistischer Infektionen bei Patienten mit fortgeschrittenem Immundefekt deutlich zurückgegangen [19]. Auch der Verlauf vieler HIV-assoziierter Komplikationen hat sich dramatisch gewandelt. Einige vor kurzem noch mit infauster Prognose belastete Infektionen wie die PML können unter HAART einen prolongierten Verlauf nehmen, andere Erkrankungen wie Kryptosporidiosen, für die bislang keine sinnvolle spezifische Therapie existiert, sind sogar kurabel [1,5].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Albrecht H, Hoffmann C, Degen O, et al. (1998) Highly active antiretroviral therapy ( HAART) significantly improves the prognosis of patients with HIV-associated progressive multifocal leuken- cephalopathy. AIDS 12: 1149–1154PubMedCrossRefGoogle Scholar
  2. 2.
    Aldeen T, Hay P, Davidson F, Lau R (1998) Herpes zoster infection in HIV-seropositive patients associated with highly active antiretroviral therapy. AIDS 13: 1719–1720Google Scholar
  3. 3.
    Autran B, Carcelain G, Li TS et al. (1997) Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277: 112–116PubMedCrossRefGoogle Scholar
  4. 4.
    Cameron DW, Heath Chiozzi M, Danner S et al. (1998) Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 351: 543–549PubMedCrossRefGoogle Scholar
  5. 5.
    Carr A, Marriott D, Field A, Vasak E, Cooper DA (1998) Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 351: 256–261PubMedCrossRefGoogle Scholar
  6. 6.
    Connors M, Kovacs Ja, Krevat S et al. (1997) HIV infection induces changes in CD4+ T cell phenotype and depletions within the CD4+ T cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Med 3: 533–540PubMedCrossRefGoogle Scholar
  7. 7.
    Currier Js, Williams Pi, Becker S et al. (1998) Incidence rates on risk factors for opportunistic infections in a phase II trial comparing indinavir + ZDV + 3TC to ZDV + 3TC. Abstract 257, 5th Conf Retrovir Opp Inf, ChicagoGoogle Scholar
  8. 8.
    Freeman W, MacDonald J, Torriani F et al. (1998) Ophthalmologic manifestations of immune recovery in AIDS patients on HAART. Abstract 757,5th Conf Retrovir Opp Inf, ChicagoGoogle Scholar
  9. 9.
    Furrer H, Malinverni R (1999) Systemic inflammatory reaction after starting highly active antiretroviral therapy in AIDS patients treated for extrapulmonary tuberculosis. Am J Med 106: 371–372PubMedCrossRefGoogle Scholar
  10. 10.
    Gorochov G, Neumann A, Kereveur A et al. (1998) Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nature Med 4: 215–221PubMedCrossRefGoogle Scholar
  11. 11.
    Hoffmann C, Horst HA, Degen O, van Lunzen J, Stellbrink HJ (1998) Manifestation of mycobacterial lymphadenitis after initiating of highly active antiretroviral therapy (HAART). Abstract 22172, 12th World AIDS Conference, GenevaGoogle Scholar
  12. 12.
    Jacobson MA, Zegans M, Pavan PR, et al. (1997) Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 349: 1443–1445PubMedCrossRefGoogle Scholar
  13. 13.
    Jiménez-Expósito MJ, Alonso-Villaverde C, Sardà P, Masana L (1999) Visceral leishmaniasis in HIV-infected patients with non-detectable HIV-1 viral load after highly active antiretroviral therapy. AIDS 13: 152–153PubMedGoogle Scholar
  14. 14.
    John M, Flexman J, French MA (1998) Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 12: 2289–2293PubMedCrossRefGoogle Scholar
  15. 15.
    Karavellas MP, Plummer DJ, Macdonald JC et al. (1999) Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successfull highly active antiretroviral therapy. J Infect Dis 179: 697–700PubMedCrossRefGoogle Scholar
  16. 16.
    Lebbé C, Blum L, Pellet C et al. (1998) Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi’s sarcoma. AIDS 12: F45–49PubMedCrossRefGoogle Scholar
  17. 17.
    Martinez E, Gatell J, Moran Y et al. (1998) High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors. Clin Infect Dis 27: 1510–1513PubMedCrossRefGoogle Scholar
  18. 18.
    Michelet C, Arvieux C, François C et al. (1998) Opportunistic infections occuring during highly active antiretroviral treatment. AIDS 12: 1815–1822PubMedCrossRefGoogle Scholar
  19. 19.
    Pallela FJ, Delaney KM, Moorman AC et al (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med, 338: 853–860CrossRefGoogle Scholar
  20. 20.
    Race E, Adelson-Mitty J, Kriegel GR et al. (1998) Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 351: 252–255PubMedCrossRefGoogle Scholar
  21. 21.
    Vento S, Garofano T, Renzini C et al. (1998) Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS 12: 116–117PubMedGoogle Scholar
  22. 22.
    Wit FW, van Leeuwen R, Weverling GJ et al. (1999) Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 179: 790–798PubMedCrossRefGoogle Scholar
  23. 23.
    Woods ML 2nd, MacGinley R, Eisen DP, Allworth AM (1998) HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection. AIDS 12: 1491–1494PubMedCrossRefGoogle Scholar
  24. 24.
    Zylberberg H, Pialoux G, Carnot F, Landau A, Bréchot C, Pol S (1998) Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Clin Infect Dis 27: 1255–1258PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2000

Authors and Affiliations

  • C. Hoffmann
  • O. Degen
  • H. A. Horst
  • J. van Lunzen
  • H.-J. Stellbrink

There are no affiliations available

Personalised recommendations